注册 English

Impurity profile of macitentan in tablet dosage form using a stability-indicating high performance liquid chromatography method and forced degradation study

Narasimha S LAKKA ,  Chandrasekar KUPPAN ,  Parthasarathy RANGASAMY

downloadPDF
引用本文: Narasimha S LAKKA,  Chandrasekar KUPPAN,  Parthasarathy RANGASAMY. Impurity profile of macitentan in tablet dosage form using a stability-indicating high performance liquid chromatography method and forced degradation study[J]. 色谱, 2019, 37(1): 100-110. doi: 10.3724/SP.J.1123.2018.06032 shu
Citation:  Narasimha S LAKKA,  Chandrasekar KUPPAN,  Parthasarathy RANGASAMY. Impurity profile of macitentan in tablet dosage form using a stability-indicating high performance liquid chromatography method and forced degradation study[J]. Chinese Journal of Chromatography, 2019, 37(1): 100-110. doi: 10.3724/SP.J.1123.2018.06032 shu

Impurity profile of macitentan in tablet dosage form using a stability-indicating high performance liquid chromatography method and forced degradation study

  • 1.

    Department of Science and Humanities, VIGNAN's Foundation for Science, Technology & Research(VFSTR), Vadlamudi, Guntur(Dist.)522213, India;

  • 2.

    Department of Analytical Research & Development, Sinotherapeutics Inc., Shanghai 201210, China

摘要: Macitentan (MAC) is a pulmonary arterial hypertension (PAH) drug marketed as a tablet and often has stability issues in the final dosage form. Quantitative determination of MAC and its associated impurities in tablet dosage form has not been previously reported. This study quantified impurities present in Macitentan tablets using a binary solvent-based gradient elution method using reversed phase-high performance liquid chromatography. The developed method was validated per International Conference on Harmonization (ICH) guidelines and the drug product was subjected to forced degradation studies to evaluate stability. The developed method efficiently separated the drug and impurities (48 min) without interference from solvents, excipients, or other impurities. The developed method met all guidelines in all characteristics with recoveries ranging from 85%-115%, linearity with r2 ≥ 0.9966, and substantial robustness. The stability-indicating nature of the method was evaluated using stressed conditions (hydrolysis:1 N HCl at 80℃/15 min; 1 N NaOH at 25℃/45 min; humidity stress (90% relative humidity) at 25℃ for 24 h, oxidation:at 6% (v/v) H2O2, 80℃/15 min, thermolysis:at 105℃/16 h and photolysis:UV light at 200 Wh/m2; Fluorescent light at 1.2 million luxh). Forced degradation experiments showed that the developed method was effective for impurity profiling. All stressed samples were assayed and mass balance was>96%. Forced degradation results indicated that MAC tablets were sensitive to hydrolysis (acid and alkali) and thermal conditions. The developed method is suitable for both assay and impurity determination, which is applicable to the pharmaceutical industry.

English

    1. [1] OPSUMIT® (Macitentan) Tablets, Label.[2018-05-31]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf

    2. [2] Hong I S, Coe H V, Catanzaro L M, et al. Ann Pharmacother, 2014, 48(4):1

    3. [3] Iglarz M, Binkert C, Morrison K, et al. J Pharmacol Exp Ther, 2008, 327:736

    4. [4] Patricia N S, Paul L M V G, Atef H, et al. Eur J Clin Pharmacol, 2011, 67:977

    5. [5] Wikizero, Macitentan.[2018-05-31]. https://www.wikizero.com/en/Macitentan

    6. [6] Gatfield J, Mueller G C, Sasse T, et al. PLoS One, 2012, 7(10):e47662

    7. [7] Olivier S, Nicholas W M. Eur Respir Rev, 2012, 21(126):321

    8. [8] Actelion Pharmaceuticals Australia Pty Ltd. Australian Public Assessment Report for Macitentan Proprietary Product Name.[2018-05-31]. https://www.tga.gov.au/sites/default/files/auspar-macitentan-140428.pdf

    9. [9] Martin H B, Christoph B, Christoph B, et al. J Med Chem, 2012, 55:7849

    10. [10] Kunal M J, Raghunath B T, Vijayavitthal T M, et al. IJSRST, 2017, 3(10):137

    11. [11] ICH Q3A(R2) Impurities in New Drug Substances.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf

    12. [12] European Medicines Agency. Guideline on Setting Specifications for Related Impurities in Antibiotics, Final.[2018-05-31]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129997.pdf

    13. [13] ICH Q3B (R2) Impurities in New Drug Products.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf

    14. [14] Nandini R P, Seema S S. Der Pharma Chemica, 2013, 5(4):274

    15. [15] Prabha S, Devarakonda V R, Raju V K V, et al. J Pharm Biomed Anal, 2010, 52:142

    16. [16] Satyanarayana R T, Vishweshwari K O, Ganesh V, et al. JPA, 2012, 2(4):272

    17. [17] Esen B A, Yucel Y, Cagan A, et al. J Pharm Biomed Anal, 2017, 136:1

    18. [18] Li C Y, Lan G J, Jiang J Y, et al. Chromatographia, 2015, 78:825

    19. [19] Siva K R, Sravan K K V, Kondareddy L, et al. J Chromatogr Sci, 2018; 56(5):383

    20. [20] Saurabh P, Preeti P, Durgesh M, et al. Braz J Pharm Sci, 2013, 49(1):175

    21. [21] Lakshmi D, Hitesh K P, Praveen M, et al. J Pharm Drug Deliv Res, 2016, 5(6)

    22. [22] Aziz U, Syed S A, Santosh K S, et al. IAJPR, 2014, 4:3836

    23. [23] Manzoor A, Deepak B M, Satishkumar S A, et al. WJPPS, 2015, 4:881

    24. [24] Oliver K, Manuel H, Felix H, et al. Eur J Pharm Sci, 2009, 38(4):384

    25. [25] Yu L, Zhou Y, He X, et al. J Chromatogr B, 2015, 1002:358

    26. [26] Alexander T, Paivi A, Ruben D K, et al. J Pharmacol Exp Ther, 2014, 350:130

    27. [27] Jin Z, Peiwu G, Xinhua L, et al. IJCEM, 2015, 8:18420

    28. [28] Shirin B, Paivi A, Marie-Claude H, et al. AAPS J, 2012, 14(1):68

    29. [29] Wu B, Li X, Cui H, et al. Anhui Medical and Pharmaceutical Journal, 2017, 21(2):248

    30. [30] Mohit T, Debasish S, Gananadhamu S, et al. Chromatographia, 2018, 81(3):525

    31. [31] ICH Q1A (R2) Stability Testing of New Drug Substances and Products.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf

    32. [32] Llyod R S, Joseph J K, Joseph G L. Practical HPLC Method Development. 2nd ed. Hoboken:John Wiley and Sons, 2010

    33. [33] Q2(R1) Validation of Analytical Procedures:Text and Methodology, 1996.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf

    34. [34] United States Pharmacopeia. USP <1225> Validation of Compendial Procedures. USP 38, 2018, 1445

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  13
  • 文章访问数:  551
  • HTML全文浏览量:  129
文章相关
  • 收稿日期:  2018-06-30
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net